Tuesday’s Highlights at Noon: La Jolla Pharma (LJPC), Teva Pharmaceutical Industries (TEVA), Cormedix (CRMD), Rite Aid (RAD), Heron Therapeutics (HRTX)

So far Tuesday, February 4, NASDAQ is up 2.55% and the S&P is up 1.73%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; La Jolla Pharma (LJPCResearch Report), Teva Pharmaceutical Industries (TEVAResearch Report), Cormedix (CRMDResearch Report), Rite Aid (RADResearch Report) and Heron Therapeutics (HRTXResearch Report).

La Jolla Pharma is up 12.76% in midday trading to $8.13. Shares opened today at $7.21. The company has a 52-week low of $2.30 and a 52-week high of $13.90. On the Street’s front, the average 12-month analyst price target for the stock is $11.33, marking a 57.14% potential upside from current levels. In a report issued on January 24, LifeScience Cap analyst Sam Slutsky maintained a Buy rating on LJPC, with a price target of $11.00, which implies an upside of 53% from current levels. Separately, on January 9, H.C. Wainwright’s Edward White maintained a Hold rating on the stock . In the last 30 days, insiders purchased $18.59M worth of LJPC shares. Over the last 3 months, the insider sentiment on La Jolla Pharma has been positive based on 90 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Teva Pharmaceutical Industries is up 5.34% in midday trading to $12.04. Shares opened today at $11.43. The company has a 52-week low of $6.07 and a 52-week high of $20.21. On the Street’s front, the average 12-month analyst price target for the stock is $9.00, marking a -21.26% potential downside from current levels. In a report released today, Oppenheimer analyst Esther Rajavelu maintained a Buy rating on TEVA, with a price target of $12.00, which represents a slight upside potential from current levels. Separately, on January 22, Wells Fargo’s David Maris maintained a Hold rating on the stock and has a price target of $10.00.

Cormedix is down -4.76% in midday trading to $6.62. Shares opened today at $6.95. The company has a 52-week low of $4.86 and a 52-week high of $13.70. On the Street’s front, the average 12-month analyst price target for the stock is $14.50, marking a 108.63% potential upside from current levels. In a report released today, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CRMD, with a price target of $14.00, which implies an upside of 101% from current levels. Over the last 3 months, the insider sentiment on Cormedix has been positive based on 17 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Rite Aid is down -4.74% in midday trading to $12.05. Shares opened today at $12.65. The company has a 52-week low of $5.04 and a 52-week high of $23.88. On the Street’s front, the average 12-month analyst price target for the stock is $12.00, marking a -5.14% potential downside from current levels. In a report issued on December 23, Deutsche Bank analyst George Hill maintained a Sell rating on RAD, with a price target of $12.00, which represents a potential downside of 5% from where the stock is currently trading.

See today’s analyst top recommended stocks >>

Heron Therapeutics is up 4.3% in midday trading to $22.05. Shares opened today at $21.14. The company has a 52-week low of $15.68 and a 52-week high of $28.70. On the Street’s front, the average 12-month analyst price target for the stock is $45.67, marking a 116.04% potential upside from current levels. In a report issued on January 15, Cowen analyst Boris Peaker maintained a Buy rating on HRTX, with a price target of $40.00, which implies an upside of 89% from current levels.

Trending Stocks Based on Insider Activity >>